Allarity Therapeutics, Inc. (ALLR)
Automate Your Wheel Strategy on ALLR
With Tiblio's Option Bot, you can configure your own wheel strategy including ALLR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALLR
- Rev/Share 0.0
- Book/Share 16.7481
- PB 0.0532
- Debt/Equity 0.0
- CurrentRatio 2.66
- ROIC -1.3726
- MktCap 13444946.0
- FreeCF/Share -16.9096
- PFCF -0.7133
- PE -0.0415
- Debt/Assets 0.0
- DivYield 0
- ROE -1.5149
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 2
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
Published: April 14, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , April 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ: ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Boston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that the securities class action lawsuit in the United States District Court for the Southern District of New York referenced in the Company's Form 10-Q filing on November 11, 2024, has been dismissed in whole against all defendants.
Read More
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Boston (February 24, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that the new protocol for its Phase 2 clinical trial of stenoparib in ovarian cancer is set to begin and will be expected to provide critical data by end of summer 2026 for a pivotal registration trial.
Read More
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities prior to May 17, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Connect
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities prior to May 17, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Reach Out
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities prior to May 17, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities prior to May 17, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.
Read More
About Allarity Therapeutics, Inc. (ALLR)
- IPO Date 2021-12-21
- Website https://www.allarity.com
- Industry Biotechnology
- CEO Mr. Thomas H. Jensen
- Employees 6